Certain characteristics of children with B-cell acute lymphoblastic leukemia (B-ALL) and race drive who receives intravenous immunoglobulin (IVIG) for infection prevention, according to research presented at the 2021 American Society of Pediatric Hematology/Oncology (ASPHO) meeting.
About 30% of patients receive IVIG for infection prevention during treatment, but evidence for administration is lacking. This study examined a retrospective cohort of 251 patients with B-cell ALL to compare patient and disease characteristics of children who received IVIG. The researchers also examined infection-related outcomes with IVIG.
A total of 113 patients in the cohort received IVIG, and 138 patients did not. Patients who received IVIG tended to be younger (P <0.01) and of non-Hispanic white ethnicity. Patients who received IVIG had more infections per 1000 treatment days.
After adjustment, race/ethnicity, IgG nadir, and the number of severe infections per 1000 treatment days were associated with IVIG receipt. Among 107 IVIG recipients, patients had fewer hospitalization days, emergency department visits, severe infections and febrile neutropenia during supplementation.
The authors concluded that certain patient characteristics are driving the physicians’ choice to give IVIG. Also, the results showed that IVIG has a favorable impact on infection-related outcomes. Future studies should investigate patient characteristics that drive IVIG administration and the association of race with IVIG receipt.
Edington H, DeGroote N, Miller T, et al. Predictors and outcomes of immunoglobulin supplementation in children with B-cell acute lymphoblastic leukemia. Poster presented at: 2021 American Society of Pediatric Hematology/Oncology meeting; April 21-23, 2021; virtual.